CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) skyrocketed 23.14% to HKD 96.640
Newtimespace News, as of 11:16 on May 11, CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) was quoted at HKD 96.640, up 23.14%. The ETF opened at HKD 90.240, with a high of HKD 98.740 and a low of HKD 90.240. The latest NAV per unit is HKD 78.339, with a premium rate of 0.18%. The asset size is approximately HKD 43.713 billion.
CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) tracks the daily performance of SK hynix Inc's (Korean Exchange code: 000660) ordinary shares, aiming to provide double (2x) the daily investment return. This product is the only leveraged exchange-traded product globally listed in Hong Kong that tracks SK Hynix. Primarily through a swap-based synthetic replication strategy, it provides investors with daily double-return opportunities, allowing them to capture the growth potential of the global memory leader, SK Hynix, amidst the AI wave. SK Hynix is a global leader in semiconductor memory manufacturing, holding a leading position in the High Bandwidth Memory (HBM) field and serving as a crucial supply chain component for AI chip giants like NVIDIA.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHI MER LAND (00978.HK): JV bid of HKD 1.03 billion for Hung Shui Kiu land accepted, constituting discloseable transaction under alternative size test
- TST PROPERTIES & SINO LAND (00247.HK/00083.HK): Consortium bid of HKD 1.03 billion for Hung Shui Kiu land accepted, JVs established for acquisition and development
- BANK OF CHINA (03988.HK): Completes issuance of RMB 20 billion write-down perpetual capital bonds at coupon rate of 1.86%
- CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
- TAI SANG LAND(00089.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 48.32 million, turned profitable from a loss YoY